By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shire Pharmaceuticals Group plc 

Hampshire International Business Park
Basingstoke  Hampshire  RG24 8EP  United Kingdom
Phone: 44-1256-894-000 Fax: 44-1256-894-708


Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its first two years of operation, the company had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter, innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer's disease and end-stage renal failure.

By 1992, Shire had embarked on the first of what would be a series of strategic acquisitions -- these were bold ventures that fortified our product lines and underscored the wisdom of a business model focused exclusively on products sold to specialist physicians. After the turn of the millennium, with the acquisition of TKT, we began our focus on rare diseases, something that remains a strategic focus for the company today. The Shire pipeline continues to be sustained by creative acquisitions and innovative licensing deals. Smart commercialization strategies have ensured that the right patients and the right physicians have the information they need to make appropriate choices about treatment options.

In June 2016, Shire completed a combination with Baxalta, creating the world’s leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. With over 22,000 employees across more than 100 countries, Shire’s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs.




FOUNDER: Harry Stratford

CEO: Flemming Ornskov

CFO: Jeffrey Poulton


Please click here for Shire job opportunities..


Please click here for clinical trial information..


Please click here for product information..


Key Statistics

Ownership: Public

Web Site: Shire
Symbol: SHPG


Company News
Shire (SHPG)'s Hemophilia A Drug Flunks Tiny Phase I Trial 5/22/2017 6:15:17 AM
The Lancet Publishes Phase ll Results From Shire (SHPG)'s Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates In Patients With Moderate-To-Severe Ulcerative Colitis 5/18/2017 7:44:57 AM
Shire (SHPG)'s $6.5 Billion Dyax (DYAX) Bet Pays Off as Lanadelumab Wows in Phase III Study 5/18/2017 5:49:43 AM
Shire (SHPG) Delivers Strong Q1 2017 Revenue Growth While Advancing Late-Stage Pipeline 5/2/2017 11:01:31 AM
Tiny Parion Sciences Seals Dry Eye Drug Deal Worth $535 Million With Biotech Giant Shire (SHPG) 5/1/2017 5:47:42 AM
Shire (SHPG) To Create 150 New Jobs At New Dublin HQ 4/28/2017 6:54:02 AM
Shire (SHPG) Granted EU Conditional Marketing Authorisation For Natpar (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism 4/26/2017 8:38:38 AM
Shire (SHPG) Initiates Phase III Clinical Trial Program For SHP640 In Infectious Conjunctivitis For Adults And Children 4/25/2017 12:31:40 PM
Shire (SHPG) Release: Vyvanse (Lisdexamfetamine Dimesylate) CII Available In A New Chewable Tablet Formulation 4/18/2017 11:16:26 AM
Shire (SHPG) Release: INTUNIV (Guanfacine Hydrochloride Prolonged Release), A Non-Stimulant For The Treatment Of ADHD, Receives Approval In Japan 3/30/2017 9:30:15 AM